NITO
Nexentis Technologies, Inc.
NASDAQ · Basic Materials · Agricultural Inputs · IL
$3.06
−15.93%Oct 12, 2026, 12:07 UTC
Nexentis Technologies announced that MitoCareX Bio is expanding its internal bioinformatics expertise to broaden disease-biology analysis in its computational drug-discovery activities.
Source:Oct 6, 2026, 13:32 UTC
Nexentis Technologies Inc. amended and restated warrants to purchase its common stock, including a warrant held by L.I.A. Pure Capital Ltd. for 1,850,000 shares at $1.00 per share, to remove provisions that caused liability classification for accounting purposes.
Sep 24, 2026, 11:50 UTC
MitoCareX appointed Prof. Dan T. Major to its Scientific Advisory Board.
Source:Sep 3, 2026, 20:20 UTC
Nexentis Technologies Inc. received a notice from NASDAQ on August 31, 2026, stating that it no longer complies with the exchange's stockholders' equity requirement under Listing Rule 5550(b)(1).
Jun 29, 2026, 12:20 UTC
Nexentis Technologies Inc. signed an addendum to a loan and partnership agreement for its Melz solar PV project in Germany, monetizing part of its investment at a $14.5 million project valuation.
Source:Jun 22, 2026, 00:00 UTC
Nexentis Technologies Inc. signed a registered direct offering and concurrent private placement on June 24, 2026, raising approximately $2.9 million through the sale of 410,998 shares of common stock and 410,998 common stock purchase warrants at $7.056 per share.